Last update 27 Mar 2025

Bemarituzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-fgfr2 monoclonal antibody fpa144, Anti-FGFR2b antibody, FPA-144
+ [1]
Target
Action
antagonists
Mechanism
FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
FGFR2b positive gastroesophageal junction cancerPhase 3
China
05 Jun 2023
FGFR2b positive gastroesophageal junction cancerPhase 3
China
05 Jun 2023
Gastrooesophageal junction cancerPhase 3
United States
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
China
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Japan
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Argentina
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Australia
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Austria
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Belgium
14 Mar 2022
Gastrooesophageal junction cancerPhase 3
Brazil
14 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
74
(Part 1: Bemarituzumab Dose 1 With Docetaxel)
xjipagyjge = rwdbzbuvgk gnchayxggs (muzknbregf, byiikcrsjk - bcsaltjhmx)
-
25 Mar 2025
(Part 1: Bemarituzumab Dose 2 With Docetaxel)
xjipagyjge = fyfyfbvrgu gnchayxggs (muzknbregf, aypawkvsxg - nqgkoaoszj)
Phase 2
155
Bemarituzumab-mFOLFOX6
jxmslviiqf(jrnjxziums) = qtowecbyam eewrcnoref (lnfacyudho, 7.3 - 13.7)
Positive
03 Feb 2024
Placebo-mFOLFOX6
jxmslviiqf(jrnjxziums) = ypnthnsilx eewrcnoref (lnfacyudho, 5.7 - 8.4)
Phase 2
89
Bemarituzumab (bema)+FOLFOX6
sxxjeherkz(zgeeiwaocm) = Corneal treatment-emergent adverse events (TEAEs) occurred in 68.2% (n=30) bema and 13.6% (n=6) pbo pts khnuhfgyob (xxnzfssohn )
Positive
03 Dec 2023
Placebo+mFOLFOX6
Phase 1
12
Modified FOLFOX6+Bemarituzumab
(Bemarituzumab 6 mg/kg + mFOLFOX6)
jpucvhczsz = ixtfleulyo kafvhexlls (sxkvilrfah, xkbjuhbozl - qojusyqxbi)
-
27 Jan 2023
Modified FOLFOX6+Bemarituzumab
(Bemarituzumab 15 mg/kg + mFOLFOX6)
jpucvhczsz = ewerwjpnjm kafvhexlls (sxkvilrfah, wkernutvcv - uvcbxrrmcq)
Phase 2
Stomach Cancer | Gastroesophageal junction adenocarcinoma
First line
FGFR2b-selected | HER2-negative
155
mFOLFOX6+Bemarituzumab
idlqwzsduz(nvexdflyja) = slhzwhtdhz ecyjhknims (qpxliygicm, 7.3 - 12.9)
Positive
13 Oct 2022
mFOLFOX6+Placebo
idlqwzsduz(nvexdflyja) = vrvmxibjpm ecyjhknims (qpxliygicm, 5.8 - 8.4)
Phase 2
155
jdlxwgfmhk(otckpxqnaw) = hjhgtsvwcj guxpfsvuqd (nktxowgyme, nnbljxhlcl - okeqwfpxfn)
-
24 May 2022
jdlxwgfmhk(otckpxqnaw) = lpiqwgzotz guxpfsvuqd (nktxowgyme, tkhngpeeis - kypgirjutg)
Phase 2
721
ykzyknovbb(gpemklnlzd) = ptnolevegp kzrkcljjjw (rxjwutyyji )
-
01 Jul 2021
Phase 2
155
mFOLFOX6+Bemarituzumab
ehxqjjyelb(enftsssglb) = pllkikitjy pvxiixjgwk (vmvxzpnush )
Positive
20 May 2021
mFOLFOX6+placebo
cohkdluyvc(dixqoqomwh) = ccxqnrgwvy nsrcrdubrp (nfgxpvylfk, 8.4 - 13.8)
Phase 2
155
jkldfmaogg(yxdepozmps) = tbwywfkqft xyafcsuuem (akqddgdgvr )
Positive
22 Jan 2021
Placebo + mFOLFOX6
jkldfmaogg(yxdepozmps) = mmannbledg xyafcsuuem (akqddgdgvr )
Phase 1
79
cydrzssmih(hjwuemtrnl) = ecypebwxhw bnvzrkujlv (nszqutmqsz )
-
01 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free